miR-2116-3p和miR-342-3p对肝细胞癌诊断及预后价值的研究

doi:10.3969/j.issn.1006-6233.2023.09.011

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1571 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨miR-342-3p和miR-2116-3p在肝细胞癌中的临床价值。方法: 该研究纳入进行根治性手术切除的HCC患者的肿瘤组织和瘤旁肝组织样本共57例,采用qRT-PCR法进行了miR-2116-3p、miR-342-3p的表达量测定并分析。结果: miR-2116-3p和miR-342-3p在肝癌组织中表达水平明显低于癌旁组织(P=0.034,P<0.001)。ROC曲线分析二者具有诊断效能(P<0.05)。miR-2116-3p表达量可以作为预测HCC患者不良预后的独立危险因素。结论: 在本研究57例样本中,miR-2116-3p以及miR-342-3p在肝炎相关的HCC组织中显著降低,具有HCC诊断价值,为潜在新的标志物;miR-2116-3p为HCC不良预后独立预测因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ： miR-2116-3p, miR-342-3p, 肝细胞癌, 诊断标志物, 预后

Abstract：Objective: To investigate the clinical value of miR-342-3p and miR-2116-3p in hepatocellular carcinoma (HCC). Methods: A total of 57 samples of tumor tissues and para-tumor liver tissues from HCC patients who underwent curative resection were included in this study. The expression levels of miR-2116-3p and miR-342-3p were measured and analyzed by qRT-PCR. Results: The expression levels of miR-2116-3p and miR-342-3p in HCC tissues were significantly lower than those in adjacent tissues (P=0.034, P<0.001). ROC curve analysis showed that the two had diagnostic efficacy (P<0.05). The expression of miR-2116-3p can be used as an independent risk factor for predicting the poor prognosis of HCC patients.Conclusion: In the 57 samples of this study, miR-2116-3p as well as miR-342-3p were significantly reduced in hepatitis-associated HCC tissues, which had diagnostic value for HCC as a potential new marker; miR-2116-3p was an independent predictor of poor prognosis in HCC.

Key words： miR-2116-3p miR-342-3p Hepatocellular carcinoma Diagnostic markers Prognosis

基金资助:河北省医学科学研究课题计划,(编号:20231381)

通讯作者: 李剑

引用本文:

白子誉, 郦尓启, 刘辉, 任长蓉, 郑彬, 孙启天, 高英梅, 张井松, 李剑. miR-2116-3p和miR-342-3p对肝细胞癌诊断及预后价值的研究[J]. 河北医学, 2023, 29(9): 1465-1472.
BAI Ziyu, LI Erqi, LIU Hui, et al. The Diagnostic and Prognostic Value of miR-2116-3p and miR-342-3p in Hepatocellular Carcinoma. HeBei Med, 2023, 29(9): 1465-1472.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.09.011 或 http://www.hbyxzzs.cn/CN/Y2023/V29/I9/1465

[1] Piero F,Dirchwolf M,Pessa MG.Biomarkers in hepatocellular carcinoma:diagnosis,prognosis and treatment response assessment[J].Cells,2020,9(6):1370.
[2] Oura K,Morishita A,Masaki T.Molecular and functional roles of microRNAs in the progression of hepatocellular carcinoma-A review[J].Int Mol Sci,2020,21(21):8362.
[3] 蔡卓玮,胡刚峰,章波.miR-203在乙型肝炎病毒相关肝细胞癌诊断及预后中的意义[J].广西医科大学学报,2022,39(11):1773-1780.
[4] Bi Y,Liu G,Yang R.MicroRNAs:novel regulators during the immune response[J].Cell Physiol,2009,218(3):467-472.
[5] 严汉兴,贺莎,文美玲,等.循环micro RNA-4516的表达分析对肝癌的诊断与预后评估研究[J].湖南师范大学学报(医学版),2018,15(3):5-10.
[6] Lao TD,Nguyen MT,Nguyen DH,et al.Upregulation of miR-155 in nasopharyngeal carcinoma patients[J].Iran Public Health,2021,50(8):1642-1647.
[7] Qu Y,Zhang H,Sun W,et al.MicroRNA-155 promotes gastric cancer growth and invasion by negatively regulating transforming growth factor-β receptor 2[J].Cancer Sci,2018,109(3):618-628.
[8] Saliminejad K,Khorram Khorshid HR,Soleymani Fard S,et al.An overview of microRNAs:Biology,functions,therapeutics and analysis methods[J].Cell Physiol,2019,234(5):5451-5465.
[9] Tang J,Li X,Cheng T,et al.miR-21-5p/SMAD7 axis promotes the progress of lung cancer[J].Thorac Cancer,2021,12(17):2307-2313.
[10] Giordano S,Columbano A.MicroRNAs:new tools for diagnosis,prognosis,and therapy in hepatocellular carcinoma[J].Hepatology,2013,57(2):840-847.
[11] Zhao L,Zhang Y.miR-342-3p affects hepatocellular carcinoma cell proliferation via regulating NF-κB pathway[J].Biochem Biophys Res Commun,2015,457(3):370-377.
[12] Liu W,Kang L,Han J,et al.miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect[J].Onco Targets Ther,2018,(11):1643-1653.
[13] Komoll RM,Hu Q,Olarewaju O,et al.MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma[J].Hepatol,2021,74(1):122-134.
[14] Bodmer D,Eleveld M,Kater-Baats E,et al.Disruption of a novel MFS transporter gene,DIRC2,by a familial renal cell carcinoma-associated t(2;3)(q35;q21)[J].Hum Mol Genet,2002,11(6):641-649.
[15] Watanabe Y,Yamasaki F,Kajiwara Y,et al.Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors:a novel approach of correlating malignancy grade and prognosis[J].Neurooncol,2010,100(3):449-457.